Bortezomib-Induced Cardiac Dysfunction in a Patient with Plasma Cell Leukemia–A Remote Complication

Authors

  • Zunaira Rafiq Department of Clinical Haematology and Bone Marrow Transplantation National Institute of Blood Diseases and Bone Marrow Transplantation ST 2/A, Block-17, Gulshan-e-Iqbal, Karachi, Pakistan.
  • Mehwesh Taj Department of Clinical Haematology and Bone Marrow Transplantation National Institute of Blood Diseases and Bone Marrow Transplantation ST 2/A, Block-17, Gulshan-e-Iqbal, Karachi, Pakistan.
  • Tahir Shamsi Department of Clinical Haematology and Bone Marrow Transplantation National Institute of Blood Diseases and Bone Marrow Transplantation ST 2/A, Block-17, Gulshan-e-Iqbal, Karachi, Pakistan.

Keywords:

Bortezomib-induced, cardiac dysfunction, plasma cell leukemia

Abstract

ABSTRACT: Bortezomib is an important proteasome inhibitor widely used in plasma cell neoplasms. An acute cardiac dysfunction is not a frequent side effect of bortezomib, but it is mentioned in literature search via multiple case reports. We have discussed here, another case of a young male diagnosed with plasma cell leukemia on treatment, presenting with sudden onset dyspnea due to an acute myocardial toxicity which subsequently upon thorough evaluation turned out to be an association with cyclical bortezomib administration.

Downloads

Published

2016-10-01

How to Cite

1.
Rafiq Z, Taj M, Shamsi T. Bortezomib-Induced Cardiac Dysfunction in a Patient with Plasma Cell Leukemia–A Remote Complication. Nat J Health Sci [Internet]. 2016Oct.1 [cited 2023Sep.24];1(1):41-4. Available from: https://ojs.njhsciences.com/index.php/njhs/article/view/157

Issue

Vol. 1 No. 1 (2016)

Section

Case Report

Most read articles by the same author(s)

1 2 > >>